AMGN240809C352500
- 0.02
- -0.01-33.33%
Amgen Newsroom
The GLP-1 Makers to Add to Your Portfolio: Tema ETFs CEO
Dow Up 614 Points On Gains For Intel, Salesforce Shares
Amgen Options Trading: A Deep Dive Into Market Sentiment
RBC Capital raised Amgen's target price to $362.
RBC Capital has raised Amgen's target price from $332 to $362 and maintains an "outperform" rating.
Amgen Stock Slides on Lowered Guidance
Amgen Price Target Raised to $381.00/Share From $360.00 by TD Cowen
Amgen | 10-Q: Q2 2024 Earnings Report
Sector Update: Health Care Stocks Retreat in Afternoon Trading
Amgen, Walt Disney Share Losses Contribute To Dow's 125-Point Fall
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
Express News | Deutsche Bank Reiterates Hold on Amgen, Lowers Price Target to $305
Amgen Is Maintained at Neutral by B of A Securities
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
Express News | RBC Capital Maintains Outperform on Amgen, Raises Price Target to $362
Heard on the Street: It Isn't Time to Worry About Wegovy Yet -- WSJ
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
Express News | Amgen Shares Down 4.2% After Co Reports Lower Q2 Profit
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
Amgen Cut to Equal-Weight From Overweight by Wells Fargo